Celastrol alleviates esophageal stricture in rats by inhibiting NLR family pyrin domain containing 3 activation

Figure 6 The effect of celastrol in preventing esophageal stricture in vivo. Data presented as mean ± SE. Statistical analysis was performed using Dunnett’s multiple comparison test, with the “vehicle” group as the control. A: Masson staining image of the esophageal stenosis area. Scale bar = 200 μm; B: Quantitative analysis of Masson staining, ^aP < 0.001; ^bP = 0.01; C: Relative thickness of the scar area, ^cP < 0.001; ^dP = 0.004, ^eP = 0.02; ^fP = 0.02; D: Representative Hematoxylin-eosin (HE) staining image of the esophageal stenosis area in rats on day 9. Scale bar = 80 μm, 20 μm; E: Cell counts in HE staining, ^gP < 0.001; ^hP = 0.001; ⁱP = 0.005; ^jP = 0.002; F: Western blot analysis of Collagen 1 (COL1) in esophageal stenosis tissues on day 9, ^kP = 0.04; ^LP < 0.001; ^mP < 0.001; ⁿP < 0.001; G: mRNA levels of COL1 in esophageal stenosis tissues on day 9, ^oP < 0.001; ^pP < 0.001; ^qP < 0.001; ^rP < 0.001; NLRP3: NLR family pyrin domain containing 3; CEL: Celastrol; PRED: Prednisolone; LPS: Lipopolysaccharide.